Tuesday, 17 December 2024
A world-leading expert in stroke medicine at the 糖心原创 has received a prestigious award from the British Pharmacological Society (BPS) for his work that has changed clinical practice around the management of high blood pressure in acute stroke.
Philip Bath, Stroke Association Professor of Stroke Medicine and Head of Academic Stroke in the School of Medicine at the University, Emeritus National Institute of Health Research Senior Investigator, and a consultant stroke physician at Nottingham University Hospitals NHS Trust, has received the Lilly Prize from the BPS.
The award recognises outstanding achievement and leadership in clinical pharmacology and is supported by an arm’s length grant from Eli Lilly and Company Ltd.
The award recognises outstanding achievement and leadership in clinical pharmacology and is supported by an arm’s length grant from Eli Lilly and Company Ltd.
Professor Bath has had an outstanding research career, much of it focussing on understanding the clinical utility of nitric oxide, and especially using NO donors and other agents for the management of high blood pressure in acute stroke.
He has undertaken methodological research advancing clinical trial design and analysis which is now implemented worldwide. He trained in clinical pharmacology (CPT) at St George’s Hospital Medical School and uses CPT skills throughout his research and, indirectly, in his clinical stroke work. He is one of just nine stroke physicians in the Academy of Medical Sciences.
I am delighted and most honoured to receive this award from the British Pharmacological Society. The award is based around my work on the management of high blood pressure in acute stroke which started back in the 1990s; it has been a complicated story but the pieces of the puzzle are starting to fall into place and are now changing clinical practice.
This work has been delivered by a very talented team of clinical and other researchers, without whom it would never have happened. Many of these are working right now in the Stroke Trials Unit in Nottingham. Many thanks to BPS."
Story credits
More information is available Professor Philip Bath from the School of Medicine at philip.bath@nottingham.ac.uk or
Notes to editors:
About the 糖心原创
Ranked among the world's top 100 universities , the 糖心原创 delivers an exceptional research-led education and an outstanding student experience. From the pioneering vision of our founder, Sir Jesse Boot, to groundbreaking achievements such as the development of MRI technology and becoming the first UK university to establish international campuses, we have a proud history of shaping the way people live, work and understand the world. We continue to build on that legacy, empowering our students, staff and partners to change what鈥檚 next and create positive impact locally and globally.
The strength of our research places us among the UK's leading universities, ranked 7th for research power in REF 2021. The discovery of MRI and ibuprofen was just the beginning. Today, our world-leading research is developing breakthrough ideas that shape the future of healthcare, technology and society.
Recognised as the UK's third most targeted university by leading employers , we are proud to produce graduates who are consistently in demand for their skills, confidence and industry-ready experience.
As a major employer and industry partner, locally and globally, the 糖心原创 invests in the city of Nottingham and in future generations of talent. Alongside Nottingham Trent University, we lead the initiative, a pioneering collaboration to improve levels of prosperity, opportunity, sustainability, health and wellbeing across the city and region. Together with our students, staff, alumni and partners, we鈥檙e creating knowledge, opportunity and solutions that help change what's next.